[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evommune Inc (EVMN)

Evommune Inc (EVMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 496,112
  • Shares Outstanding, K 36,292
  • Annual Sales, $ 13,000 K
  • Annual Income, $ -68,870 K
  • EBIT $ -102 M
  • EBITDA $ -101 M
  • 60-Month Beta N/A
  • Price/Sales 39.14
  • Price/Cash Flow N/A
  • Price/Book 1.82

Options Overview Details

View History
  • Implied Volatility 136.45% (-13.85%)
  • Historical Volatility 68.08%
  • IV Percentile 39%
  • IV Rank 28.89%
  • IV High 247.85% on 06/22/26
  • IV Low 91.19% on 05/15/26
  • Expected Move (DTE 24) 0.85 (6.16%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 1,102
  • Open Int (30-Day) 2,628
  • Expected Range 12.94 to 14.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.82
  • Number of Estimates 6
  • High Estimate $-0.67
  • Low Estimate $-1.01
  • Prior Year $-8.07
  • Growth Rate Est. (year over year) +89.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.80 +27.69%
on 07/31/26
15.06 -8.43%
on 08/19/26
+2.43 (+21.39%)
since 07/24/26
3-Month
10.47 +31.71%
on 07/23/26
25.87 -46.70%
on 06/26/26
-9.08 (-39.70%)
since 05/22/26

Most Recent Stories

More News
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated...

EVMN : 13.79 (+0.88%)
Evommune: Can Three Readouts This Year Actually Clarify What This Pipeline Is Worth?

Barchart Research What to Expect from EVMN Earnings EVMN Generated August 5, 2026 Current Price $13.02 EPS Estimate $$-0.68 Consensus Rating Moderate Buy Average Move 5.34% Evommune: Can Three Readouts...

EVMN : 13.79 (+0.88%)
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology ‑ EVO756 designed to inhibit...

EVMN : 13.79 (+0.88%)
Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session.

EVMN : 13.79 (+0.88%)
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)

Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier -- days before the Company disclosed that EVO756 failed its Phase 2b primary endpoint.

EVMN : 13.79 (+0.88%)
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria 

- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks - Evommune to continue development of EVO756 in Atopic Dermatitis...

EVMN : 13.79 (+0.88%)
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials ...

EVMN : 13.79 (+0.88%)
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Company to showcase expansion opportunity for EVO756 (MRGPRX2 Antagonist) into third indication of migraine prophylaxis; Phase 2b study to initiate in 3Q26

EVMN : 13.79 (+0.88%)
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data...

EVMN : 13.79 (+0.88%)
Evommune Announces $125 Million Private Placement

Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today...

EVMN : 13.79 (+0.88%)

Business Summary

Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 15.13
2nd Resistance Point 14.79
1st Resistance Point 14.29
Last Price 13.79
1st Support Level 13.45
2nd Support Level 13.10
3rd Support Level 12.60

See More

52-Week High 33.20
Fibonacci 61.8% 24.52
Fibonacci 50% 21.84
Fibonacci 38.2% 19.15
Last Price 13.79
52-Week Low 10.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.